Although a significant increase in IDO was observed, no significant differences were found in the percentage of Foxp3+ Tregs in patients treated with DR-HC compared to those on conventional GCs, suggesting that the role of Tregs in the maintenance of adrenal insufficiency remains unclear and warrants further investigation. The gene discussed is IDO1; the disease is Adrenal insufficiency.